Zum Inhalt springen

mRNA-Medikament soll Lipide im Blut senken

Laut einer placebokontrollierten und doppelblinden Studie unter der Leitung von Forschern des Brigham and Women’s Hospital, einem Gründungsmitglied des Mass General Brigham-Gesundheitssystems, könnte eine experimentelle Behandlung die Triglyceride im Blut weiter senken. Die Ergebnisse wurden auf der Annual Scientific Session & Expo des American College of Cardiology 2024 vorgestellt und gleichzeitig im New England Journal of Medicine veröffentlicht. Im Rahmen der Studie wurden 154 Erwachsene, die eine lipidsenkende Therapie mit mittelschwerer oder schwerer Hypertriglyceridämie erhielten, randomisiert und erhielten entweder 50 mg Olezarsen, 80 mg Olezarsen oder Placebo. Olezarsen ist ein Antisense-Oligonukleotid, das APOC3 hemmt , ein Gen, das mit höheren Triglyceridspiegeln verbunden ist, indem es auf seine mRNA abzielt. Das subkutane Medikament wurde über einen Zeitraum von einem Jahr alle vier Wochen verabreicht. Im Vergleich zu Placebo senkte Olezarsen den Triglyceridspiegel bei der 50-mg-Dosis um 49 % und bei der… 

more »mRNA-Medikament soll Lipide im Blut senken

Prostate cancer screening with PSA, Kallikrein Panel, and MRI

In this preliminary descriptive report from an ongoing randomized clinical trial, one additional high-grade cancer per 196 men and one low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to undergo screening. These preliminary findings from a single round of screening should be interpreted cautiously, pending results of the study’s primary mortality outcome. Authors: Anssi Auvinen, M.D., Ph.D., of Tampere University in Tampere, Finland, is the corresponding author. https://jamanetwork.com/journals/jama/fullarticle/2817323?guestAccessKey=0ec76eb2-a05b-4ae3-b31c-7a662e979189&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040624

Oral vaccine for UTI is potential alternative to antibiotics

Recurrent Urinary Tract Infections (UTIs) can be prevented for up to nine years in more than half of people given an oral spray-based vaccine and is a potential alternative to antibiotic treatments, finds research. Initial results from the first long-term follow-up study of the safety and effectiveness of the MV140 vaccine for recurrent UTIs are presented this weekend at the European Association of Urology (EAU) Congress in Paris. They show that in both men and women with recurrent UTIs, 54% of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported. Full results of the study are expected to be published by the end of 2024.

EHRA 2024:  New evidence links passive smoking with dangerous heart rhythm disorder

Exposure to secondhand smoke – even at small amounts – is linked with greater risk of a serious heart rhythm disorder, according to research presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC). The likelihood of atrial fibrillation increased as the duration of passive smoking lengthened. “The dangers of secondhand smoke were significant regardless of whether individuals were at home, outdoors, or at work, indicating that exposure universally elevates the risk of atrial fibrillation,” said study author Dr. Kyung-Yeon Lee of Seoul National University Hospital, Seoul, Republic of Korea. “We should all make every effort to avoid spending time in smoky environments. The findings should also drive policymakers to further curb smoking in public areas and support smoking cessation programmes to improve public health.” https://esc365.escardio.org/EHRA-Congress/sessions/10100

Experimental drug could further reduce lipids in the blood in high-risk patients

An experimental treatment could further lower triglycerides in the blood, according to a placebo-controlled and double-blind trial led by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system. Results were presented at the 2024 American College of Cardiology’s Annual Scientific Session & Expo and simultaneously published in the New England Journal of Medicine. The trial randomized 154 adults on lipid-lowering therapy with moderate or severe hypertriglyceridemia to receive either 50mg olezarsen, 80mg olezarsen or placebo. Olezarsen is an antisense oligonucleotide that inhibits APOC3, a gene associated with higher levels of triglycerides, by targeting its mRNA. The subcutaneous medication was administered every four weeks, for a period of a year. Olezarsen reduced triglyceride levels by 49% at the 50mg dose and 53% at the 80mg dose, compared with placebo. The experimental drug also reduced… 

more »Experimental drug could further reduce lipids in the blood in high-risk patients


Antengene Presents Four Preclinical Posters at AACR 2024

Antengene announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States. The posters showcased four of Antengene’s high-potential emerging programs, including ATG-042, tracking to a H1 2025 IND filing; ATG-022, in Phase II dose expansion studies in China and Australia; AnTenGagerTM platform, Antengene’s proprietary T-cell engager (TCE) platform; and ATG-102, which could be the first IND candidate from AnTenGagerTM platform.

Antengene Presents Four Preclinical Posters at AACR 2024

Antengene announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States. The posters showcased four of Antengene’s high-potential emerging programs, including ATG-042, tracking to a H1 2025 IND filing; ATG-022, in Phase II dose expansion studies in China and Australia; AnTenGagerTM platform, Antengene’s proprietary T-cell engager (TCE) platform; and ATG-102, which could be the first IND candidate from AnTenGagerTM platform.